Olema Pharmaceuticals Shares Drop 15.1% After AstraZeneca Trial Results
Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 15.1% in pre-market trading, dropping to $8.68, after AstraZeneca disclosed that its Phase 3 SERENA-4 trial of camizestrant failed to meet its primary endpoint. AstraZeneca reported that the combination of camizestrant and palbociclib did not show a statistically significant improvement in progression-free survival for patients with ER-positive, HER2-negative advanced breast cancer.
This development has prompted investors to reassess the implications for Olema's lead candidate, palazestrant (OP-1250), which is currently being evaluated in the pivotal Phase 3 OPERA-01 trial. Palazestrant is an oral selective estrogen receptor degrader and complete estrogen receptor antagonist, sharing a similar mechanism with camizestrant. However, the outcome of AstraZeneca's trial does not directly influence the results of Olema's separate clinical program.
For Your Trading Desk
Sponsor Spike Success.
The SERENA-4 results come on the heels of Roche's persevERA trial, which also failed to meet its objectives in the first-line advanced breast cancer setting earlier this year. Following the AstraZeneca announcement, Stifel adjusted its price target for Olema, reducing it from $48 to $30 while maintaining a Buy rating.
Investors Await Key Trial Results Amidst Stock Volatility
Investors are now awaiting the top-line results from Olema's OPERA-01 Phase 3 trial, which will provide critical clinical data specific to palazestrant. Despite the recent decline, Olema shares were still trading above their 52-week low of $6.65, in contrast to a 52-week high of $36.26.
The pre-market decline in Olema's stock occurred during a broader downturn for U.S. equities, with the Nasdaq dropping 1.7% and the S&P 500 declining by 0.7%. The market's reaction to the SERENA-4 results and Stifel's price target adjustment reflects ongoing investor concerns regarding the potential impact on Olema's development program for palazestrant.




